Welcome to our dedicated page for Mineralys Therapeutics SEC filings (Ticker: MLYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mineralys Therapeutics, Inc. filings document the public-company disclosures of a biopharmaceutical issuer developing lorundrostat for hypertension and related comorbidities driven by dysregulated aldosterone. Form 8-K reports cover quarterly and annual financial results, corporate updates, Regulation FD disclosures, FDA acceptance of the lorundrostat New Drug Application, and clinical results from the Explore-OSA exploratory trial.
The filing record also includes proxy materials for annual meeting voting and stockholder procedures, along with material-event disclosures for capital-structure matters. These include common stock arrangements under an ATM Equity Offering Sales Agreement, registration-statement references, material agreements, and shareholder voting matters.
Mineralys Therapeutics Chief Medical Officer David Malcom Rodman reported a mix of option exercises and share sales in mid-June. On June 15 and June 17, he sold a total of 14,474 shares of common stock in open-market transactions at weighted-average prices around $23.81 and $25.00.
To support these sales, he exercised stock options covering 8,126 shares at exercise prices of $10.20, $14.25 and $15.44. After the transactions, he directly holds 57,095 shares of common stock. The filing notes that the trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025.
Mineralys Therapeutics director Daphne Karydas exercised stock options for 3,000 shares of common stock at $12.02 per share and sold 3,000 shares at $25.00 per share. After these transactions, she holds 6,200 shares directly. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025.
Mineralys Therapeutics (MLYS) filed a Form 144 stating an intended sale of 4,584 shares of common stock in a broker assisted cashless exercise related to an exercise of employee stock options on 06/17/2026. The filing lists prior open-market sales by David Rodman from 03/12/2026 through 06/15/2026 with multiple share quantities and dollar amounts.
Mineralys Therapeutics, Inc. reported a Rule 144 notice for the sale of 3,000 shares of Common Stock via a broker-assisted cashless exercise on 06/17/2026. The filing shows proceeds of $75,000 and identifies the seller as Daphne Karydas. The transaction is described as an exercise of employee stock options.
Mineralys Therapeutics filed a Form 144 reporting proposed sales of common stock and recent dispositions by an affiliate. The notice lists a broker-assisted cashless exercise that produced 3,542 shares on 06/15/2026 and earlier RSU vesting of 6,348 shares on 02/28/2023. The filing also itemizes multiple sales by David Rodman between 03/09/2026 and 06/12/2026 with single-trade proceeds shown for each transaction.
Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom reported option exercises and related stock sales. On June 12, 2026, he exercised options for 6,349 shares of common stock at $1.08 per share and sold 6,349 shares in an open-market transaction at a weighted-average price of $23.9252 per share under a pre-arranged Rule 10b5-1 trading plan. On June 10, 2026, he exercised options for 2,170 shares at $16.00 per share and sold 2,170 shares at $25.00 per share. Following these transactions, Malcom directly holds 63,443 shares of Mineralys common stock.
Mineralys Therapeutics, Inc. submitted a Rule 144 notice disclosing the sale of 6,349 shares of Common Stock on 06/12/2026 via a broker‑assisted cashless exercise of employee stock options. The filing also lists multiple open‑market dispositions by David Rodman totaling repeated sales during March–June 2026 with individual lot sizes shown.
Mineralys Therapeutics filed a Form 144 notice reporting a proposed sale of 2,170 shares of Common Stock via a broker-assisted cashless exercise on 06/10/2026. The filing lists multiple recent dispositions by the reporting person between 03/09/2026 and 05/18/2026, including sales of 14,058 shares on 03/13/2026 for $369,225.07 and repeated smaller transactions. This notice documents affiliated share sales and an associated cashless exercise; timing and settlement mechanics are described as a broker-assisted cashless exercise.
Mineralys Therapeutics, Inc. entered into an underwriting agreement for a primary offering of 5,660,378 shares of common stock at $26.50 per share. Underwriters will purchase the shares at $25.3075 per share, and net proceeds to Mineralys are expected to be about $142.5 million after fees and expenses.
The offering is expected to close on or about June 4, 2026, subject to customary conditions, and is being conducted under an effective shelf registration statement and prospectus supplement. In its press release, Mineralys stated it intends to use the net proceeds to help fund a $200.0 million upfront payment to repurchase a royalty obligation under its license agreement with Tanabe Pharma Corporation, alongside a previously announced $500 million committed debt facility from funds managed by Pharmakon Advisors.
Mineralys Therapeutics, Inc. entered into an underwriting agreement for a primary offering of 5,660,378 shares of common stock at $26.50 per share. Underwriters will purchase the shares at $25.3075 per share, and net proceeds to Mineralys are expected to be about $142.5 million after fees and expenses.
The offering is expected to close on or about June 4, 2026, subject to customary conditions, and is being conducted under an effective shelf registration statement and prospectus supplement. In its press release, Mineralys stated it intends to use the net proceeds to help fund a $200.0 million upfront payment to repurchase a royalty obligation under its license agreement with Tanabe Pharma Corporation, alongside a previously announced $500 million committed debt facility from funds managed by Pharmakon Advisors.
Mineralys Therapeutics is offering 5,660,378 shares of common stock. The prospectus supplement states an offering price of $26.50 per share and lists gross proceeds of $150,000,017 with underwriting discounts of $6,750,001, producing proceeds before expenses to the company of $143,250,016.
The company says it expects to receive approximately $142.5 million in net proceeds and intends to use those funds to finance a portion of a $200.0 million upfront payment to repurchase a royalty obligation under its license agreement with Tanabe Pharma Corporation. The supplement also discloses shares outstanding of 82,454,950 as of March 31, 2026, and projects 88,115,328 shares outstanding immediately after this offering.
Mineralys Therapeutics is offering 5,660,378 shares of common stock. The prospectus supplement states an offering price of $26.50 per share and lists gross proceeds of $150,000,017 with underwriting discounts of $6,750,001, producing proceeds before expenses to the company of $143,250,016.
The company says it expects to receive approximately $142.5 million in net proceeds and intends to use those funds to finance a portion of a $200.0 million upfront payment to repurchase a royalty obligation under its license agreement with Tanabe Pharma Corporation. The supplement also discloses shares outstanding of 82,454,950 as of March 31, 2026, and projects 88,115,328 shares outstanding immediately after this offering.